MAB Mabion S.A.

2.337USD9.400 PLN · GPW-0.42%Mkt Cap: 37.77M USDP/E: —

Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell lin…

Key Statistics

Company
Market Cap37.77M USD
Enterprise Value41.75M USD
Revenue (TTM)4.11M USD
Gross Profit-4.33M USD
Net Income (TTM)-15.57M USD
Revenue/Share0.25 USD
Last Price2.337 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees199
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLMBION00016
Valuation
P/E (Trailing)—
P/E (Forward)-4.23
PEG—
EV/EBITDA-6.10
EV/Revenue10.16
P/S9.19
P/B3.11
EPS (TTM)-0.96 USD
EPS (Forward)-0.55 USD
52W Range
1.66660% of range2.789
52W High2.789 USD
52W Low1.666 USD
Profitability
Gross Margin-110.52%
Oper. Margin-223.51%
EBITDA Margin-166.58%
Profit Margin-397.37%
ROE-128.23%
ROA-56.70%
ROIC-91.33%
ROCE-75.64%
Growth
Revenue Growth-26.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.34M USD
CapEx (TTM)221.76K USD
FCF Margin-231.63%
FCF Yield-25.19%
Net Debt3.88M USD
Net Debt/EBITDA-0.57
Net Debt/FCF—
Balance Sheet
Debt/Equity0.26
Current Ratio0.66
Quick Ratio0.06
Book Value/Sh0.75 USD
Cash/Share0.0045 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.16.16M
Float11.45M
Insiders28.98%
Institutions0.00%
Technical
SMA 502.009 (+16.3%)
SMA 2001.969 (+18.7%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)87.63K
Avg Vol (10d)205.99K
Technical Indicators
RSI (14)63.7
MACD0.4489
MACD Signal0.2908
MACD Hist.+0.1581
BB Upper2.566 USD
BB Middle2.105 USD
BB Lower1.644 USD
BB Width43.82%
ATR (14)0.1267 USD
Vol Ratio (20d)0.28x

About Mabion (WSE: MAB)

›

Mabion (WSE: MAB) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 199 employees.

The shares were at 9.400 PLN on 19 November 2026, up 15.3% over 52 weeks. Its 52-week range is 6.700 PLN to 11.22 PLN: the price is 16.2% below the high and 40.3% above the low.

Its market capitalisation is 151.93M PLN.

Mabion reports return on equity of -128.2%, an operating margin of -223.5% and revenue down 26.7% year over year.

Its debt exceeds its cash by 15.63M PLN, a debt-to-equity ratio of 0.26. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.